New targeted chemo aims to hit tumors harder, spare healthy tissue
NCT ID NCT04969835
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests AVA6000, a chemotherapy drug that is designed to activate only in tumors, potentially reducing side effects. About 158 adults with advanced solid tumors (like breast, ovarian, or salivary gland cancer) will receive the drug intravenously. The main goals are to check safety and find the right dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AVA6000 (a targeted form of the chemotherapy drug doxorubicin, designed to activate only in tumors)
What this could lead to
If successful, this could lead to a more targeted chemotherapy that reduces side effects by activating only in tumors.
What could go wrong
This is a very early Phase 1 trial, so safety and effectiveness are not yet known. It may not work or could have unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fred Hutchinson Cancer Center
RECRUITINGSeattle, Washington, 98109, United States
Contact
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact
-
St James's University Hospital, The Leeds Teaching Hospitals NHS Trust
RECRUITINGLeeds, LS9 7TF, United Kingdom
Contact
-
The Beatson West of Scotland Cancer Centre, NHS Greater Glasgow & Clyde
RECRUITINGGlasgow, G12 0YN, United Kingdom
Contact
-
The Christie NHS Foundation Trust
RECRUITINGManchester, M20 4BX, United Kingdom
Contact
-
The Freeman Hospital, Newcastle-upon-Tyne NHS Foundation Trust
RECRUITINGNewcastle upon Tyne, NE7 7DN, United Kingdom
Contact
-
The Royal Marsden, NHS Foundation Trust
RECRUITINGLondon, SM2 5PT, United Kingdom
Contact
-
University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
Weston Park Cancer Centre, Sheffield Teaching Hospitals NHS Foundation Trust
NOT_YET_RECRUITINGSheffield, S10 2SJ, United Kingdom
Contact